Ventilator Associated Pneumonia Therapeutics Market
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Prevention
1.2.3 Physiotherapy
1.2.4 Immunity Therapy
1.3 Market by Application
1.3.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Center
1.3.4 Diagnostic Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Perspective (2017-2028)
2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Growth Trends by Region
2.2.1 Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Market Dynamics
2.3.1 Ventilator Associated Pneumonia (VAP) Therapeutics Industry Trends
2.3.2 Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers
2.3.3 Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges
2.3.4 Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue
3.1.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue
3.4 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio
3.4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2021
3.5 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players Head office and Area Served
3.6 Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service
3.7 Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Type
4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2023-2028)
5 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Application
5.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
6.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
6.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
7.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
7.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
8.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
9.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
9.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
10.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Achaogen
11.1.1 Achaogen Company Detail
11.1.2 Achaogen Business Overview
11.1.3 Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.1.4 Achaogen Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.1.5 Achaogen Recent Development
11.2 Adenium Biotech
11.2.1 Adenium Biotech Company Detail
11.2.2 Adenium Biotech Business Overview
11.2.3 Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.2.4 Adenium Biotech Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.2.5 Adenium Biotech Recent Development
11.3 Aridis Pharmaceuticals
11.3.1 Aridis Pharmaceuticals Company Detail
11.3.2 Aridis Pharmaceuticals Business Overview
11.3.3 Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.3.4 Aridis Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.3.5 Aridis Pharmaceuticals Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Detail
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.4.4 AstraZeneca Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.4.5 AstraZeneca Recent Development
11.5 Bayer
11.5.1 Bayer Company Detail
11.5.2 Bayer Business Overview
11.5.3 Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.5.4 Bayer Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.5.5 Bayer Recent Development
11.6 Cardeas Pharma
11.6.1 Cardeas Pharma Company Detail
11.6.2 Cardeas Pharma Business Overview
11.6.3 Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.6.4 Cardeas Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.6.5 Cardeas Pharma Recent Development
11.7 Destiny Pharma
11.7.1 Destiny Pharma Company Detail
11.7.2 Destiny Pharma Business Overview
11.7.3 Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.7.4 Destiny Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.7.5 Destiny Pharma Recent Development
11.8 Dong-A Socio Holdings
11.8.1 Dong-A Socio Holdings Company Detail
11.8.2 Dong-A Socio Holdings Business Overview
11.8.3 Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.8.4 Dong-A Socio Holdings Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.8.5 Dong-A Socio Holdings Recent Development
11.9 Lakewood-Amedex
11.9.1 Lakewood-Amedex Company Detail
11.9.2 Lakewood-Amedex Business Overview
11.9.3 Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.9.4 Lakewood-Amedex Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.9.5 Lakewood-Amedex Recent Development
11.10 MedImmune
11.10.1 MedImmune Company Detail
11.10.2 MedImmune Business Overview
11.10.3 MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.10.4 MedImmune Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.10.5 MedImmune Recent Development
11.11 Meiji Seika Pharma
11.11.1 Meiji Seika Pharma Company Detail
11.11.2 Meiji Seika Pharma Business Overview
11.11.3 Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.11.4 Meiji Seika Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.11.5 Meiji Seika Pharma Recent Development
11.12 Merck & Co
11.12.1 Merck & Co Company Detail
11.12.2 Merck & Co Business Overview
11.12.3 Merck & Co Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.12.4 Merck & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.12.5 Merck & Co Recent Development
11.13 Motif Bio
11.13.1 Motif Bio Company Detail
11.13.2 Motif Bio Business Overview
11.13.3 Motif Bio Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.13.4 Motif Bio Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.13.5 Motif Bio Recent Development
11.14 Nabriva Therapeutics
11.14.1 Nabriva Therapeutics Company Detail
11.14.2 Nabriva Therapeutics Business Overview
11.14.3 Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.14.4 Nabriva Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.14.5 Nabriva Therapeutics Recent Development
11.15 Polyphor
11.15.1 Polyphor Company Detail
11.15.2 Polyphor Business Overview
11.15.3 Polyphor Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.15.4 Polyphor Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.15.5 Polyphor Recent Development
11.16 Shionogi & Co
11.16.1 Shionogi & Co Company Detail
11.16.2 Shionogi & Co Business Overview
11.16.3 Shionogi & Co Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.16.4 Shionogi & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.16.5 Shionogi & Co Recent Development
11.17 Tetraphase Pharmaceuticals
11.17.1 Tetraphase Pharmaceuticals Company Detail
11.17.2 Tetraphase Pharmaceuticals Business Overview
11.17.3 Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.17.4 Tetraphase Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.17.5 Tetraphase Pharmaceuticals Recent Development
11.18 The Medicines Company
11.18.1 The Medicines Company Company Detail
11.18.2 The Medicines Company Business Overview
11.18.3 The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.18.4 The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.18.5 The Medicines Company Recent Development
11.19 Theravance Biopharma
11.19.1 Theravance Biopharma Company Detail
11.19.2 Theravance Biopharma Business Overview
11.19.3 Theravance Biopharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.19.4 Theravance Biopharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.19.5 Theravance Biopharma Recent Development
11.20 Wockhardt
11.20.1 Wockhardt Company Detail
11.20.2 Wockhardt Business Overview
11.20.3 Wockhardt Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.20.4 Wockhardt Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.20.5 Wockhardt Recent Development
11.21 Zavante Therapeutics
11.21.1 Zavante Therapeutics Company Detail
11.21.2 Zavante Therapeutics Business Overview
11.21.3 Zavante Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.21.4 Zavante Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
11.21.5 Zavante Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Prevention
Table 3. Key Players of Physiotherapy
Table 4. Key Players of Immunity Therapy
Table 5. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region (2017-2022)
Table 9. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region (2023-2028)
Table 11. Ventilator Associated Pneumonia (VAP) Therapeutics Market Trends
Table 12. Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers
Table 13. Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges
Table 14. Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints
Table 15. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Players (2017-2022)
Table 17. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2021)
Table 18. Ranking of Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service
Table 22. Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2017-2022)
Table 26. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2023-2028)
Table 28. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Application (2017-2022)
Table 30. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Application (2023-2028)
Table 32. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 33. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 34. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 35. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 36. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 37. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 38. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 39. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 40. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 41. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 42. Achaogen Company Detail
Table 43. Achaogen Business Overview
Table 44. Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 45. Achaogen Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 46. Achaogen Recent Development
Table 47. Adenium Biotech Company Detail
Table 48. Adenium Biotech Business Overview
Table 49. Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 50. Adenium Biotech Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 51. Adenium Biotech Recent Development
Table 52. Aridis Pharmaceuticals Company Detail
Table 53. Aridis Pharmaceuticals Business Overview
Table 54. Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 55. Aridis Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 56. Aridis Pharmaceuticals Recent Development
Table 57. AstraZeneca Company Detail
Table 58. AstraZeneca Business Overview
Table 59. AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 60. AstraZeneca Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 61. AstraZeneca Recent Development
Table 62. Bayer Company Detail
Table 63. Bayer Business Overview
Table 64. Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 65. Bayer Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 66. Bayer Recent Development
Table 67. Cardeas Pharma Company Detail
Table 68. Cardeas Pharma Business Overview
Table 69. Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 70. Cardeas Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 71. Cardeas Pharma Recent Development
Table 72. Destiny Pharma Company Detail
Table 73. Destiny Pharma Business Overview
Table 74. Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 75. Destiny Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 76. Destiny Pharma Recent Development
Table 77. Dong-A Socio Holdings Company Detail
Table 78. Dong-A Socio Holdings Business Overview
Table 79. Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 80. Dong-A Socio Holdings Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 81. Dong-A Socio Holdings Recent Development
Table 82. Lakewood-Amedex Company Detail
Table 83. Lakewood-Amedex Business Overview
Table 84. Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 85. Lakewood-Amedex Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 86. Lakewood-Amedex Recent Development
Table 87. MedImmune Company Detail
Table 88. MedImmune Business Overview
Table 89. MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 90. MedImmune Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 91. MedImmune Recent Development
Table 92. Meiji Seika Pharma Company Detail
Table 93. Meiji Seika Pharma Business Overview
Table 94. Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
Table 95. Meiji Seika Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 96. Meiji Seika Pharma Recent Development
Table 97. Merck & Co Company Detail
Table 98. Merck & Co Business Overview
Table 99. Merck & Co Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
Table 100. Merck & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 101. Merck & Co Recent Development
Table 102. Motif Bio Company Detail
Table 103. Motif Bio Business Overview
Table 104. Motif Bio Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
Table 105. Motif Bio Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 106. Motif Bio Recent Development
Table 107. Nabriva Therapeutics Company Detail
Table 108. Nabriva Therapeutics Business Overview
Table 109. Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
Table 110. Nabriva Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 111. Nabriva Therapeutics Recent Development
Table 112. Polyphor Company Detail
Table 113. Polyphor Business Overview
Table 114. Polyphor Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
Table 115. Polyphor Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 116. Polyphor Recent Development
Table 117. Shionogi & Co Company Detail
Table 118. Shionogi & Co Business Overview
Table 119. Shionogi & Co Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
Table 120. Shionogi & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 121. Shionogi & Co Recent Development
Table 122. Tetraphase Pharmaceuticals Company Detail
Table 123. Tetraphase Pharmaceuticals Business Overview
Table 124. Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
Table 125. Tetraphase Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 126. Tetraphase Pharmaceuticals Recent Development
Table 127. The Medicines Company Company Detail
Table 128. The Medicines Company Business Overview
Table 129. The Medicines Company Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
Table 130. The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 131. The Medicines Company Recent Development
Table 132. Theravance Biopharma Company Detail
Table 133. Theravance Biopharma Business Overview
Table 134. Theravance Biopharma Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
Table 135. Theravance Biopharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 136. Theravance Biopharma Recent Development
Table 137. Wockhardt Company Detail
Table 138. Wockhardt Business Overview
Table 139. Wockhardt Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
Table 140. Wockhardt Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 141. Wockhardt Recent Development
Table 142. Zavante Therapeutics Company Detail
Table 143. Zavante Therapeutics Business Overview
Table 144. Zavante Therapeutics Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
Table 145. Zavante Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
Table 146. Zavante Therapeutics Recent Development
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type: 2021 VS 2028
Figure 2. Prevention Features
Figure 3. Physiotherapy Features
Figure 4. Immunity Therapy Features
Figure 5. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application in 2021 & 2028
Figure 6. Hospitals Case Studies
Figure 7. Ambulatory Surgical Center Case Studies
Figure 8. Diagnostic Centers Case Studies
Figure 9. Ventilator Associated Pneumonia (VAP) Therapeutics Report Years Considered
Figure 10. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region: 2021 VS 2028
Figure 13. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Players in 2021
Figure 14. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2021
Figure 16. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 17. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2017-2028)
Figure 18. United States Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Canada Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2017-2028)
Figure 22. Germany Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. France Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. U.K. Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Italy Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Russia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Nordic Countries Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region (2017-2028)
Figure 30. China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. South Korea Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Australia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2017-2028)
Figure 38. Mexico Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Brazil Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2017-2028)
Figure 42. Turkey Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Saudi Arabia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Achaogen Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 45. Adenium Biotech Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 46. Aridis Pharmaceuticals Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 47. AstraZeneca Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 48. Bayer Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 49. Cardeas Pharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 50. Destiny Pharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 51. Dong-A Socio Holdings Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 52. Lakewood-Amedex Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 53. MedImmune Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 54. Meiji Seika Pharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 55. Merck & Co Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 56. Motif Bio Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 57. Nabriva Therapeutics Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 58. Polyphor Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 59. Shionogi & Co Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 60. Tetraphase Pharmaceuticals Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 61. The Medicines Company Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 62. Theravance Biopharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 63. Wockhardt Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 64. Zavante Therapeutics Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Industry Market Size
